Nicolas TRICAUD PhD, world renown scientist in the field of myelin and peripheral nerves, announces the incorporation of NERVOSAVE THERAPEUTICS (SAS) inMontpellier, France. NERVOSAVE THERAPEUTICS is a spinoff of INSERM supported by SATT AxLR, Region Occitanie and BIC Montpellier. NERVOSAVE THERAPEUTICS is building a technology platform to deliver advanced therapeutic products for peripheral nerve diseases. Its first product is a clinical phase entering gene therapy to treat patients suffering from Charcot-Marie-Tooth disease 1A (CMT 1A).
Additionally, NERVOSAVE THERAPEUTICS is generating a pipeline to treat other demyelinating CMT diseases, acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome and peripheral nerve tumours.

Verbatim : Nicolas Tricaud (acting CEO and CSO):
“NERVOSAVE THERAPEUTICS is the first biotech totally dedicated to solving the problem of peripheral nerve diseases. Our ambition is to leverage the promise of gene therapy and other advanced therapies to grow NERVOSAVE THERAPEUTICS as an international leader in the field of peripheral nerve diseases in the next 5 years. The millions patients suffering these dreadful and mostly unaddressed diseases deserve our best effort in this objective”.